Payment overview · 2025
General Payments
$1,068.52
31 reported records · 12 companies
Healthcare provider profile · identity verified
Razel Barkley, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · FREDERICK, MD · NPI 1437609575
Verified facts
What the public records show
CMS Open Payments records show Razel Barkley, CRNP received $1,068.52 in general payments during 2025 across 31 reported records.
Globus Medical, Inc. accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $234.76 | 22.0% | 6 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$177.54 | 16.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $177.38 | 16.6% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $176.79 | 16.6% | 3 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $136.91 | 12.8% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $46.16 | 4.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.28 | 2.3% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $22.44 | 2.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.69 | 1.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 1.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.02 | 1.7% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.70 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,049.67 | 30 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $211.34 | 5 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $168.75 | 9 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $155.09 | 2 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $144.80 | 1 | 2025 |
Source payment records
|
|||||
| MILD DEVICE KIT Normalized: mild device kit |
Device | Stryker Corporation | $136.91 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $106.88 | 7 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $46.16 | 2 | 2025 |
Source payment records
|
|||||
| SYNCHROMEDII Normalized: synchromedii |
Device | Medtronic, Inc. | $32.74 | 2 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| Vyrsa V1 Normalized: vyrsa v1 |
Device | Globus Medical, Inc. | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| OCTRODE Normalized: octrode |
Device | Abbott Laboratories | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $8.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 107 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ozempic | Semaglutide | 202 | 51 |
| Glipizide Er | Glipizide | 190 | 69 |
| Metformin Hcl Er | Metformin Hcl | 163 | 55 |
| Metformin Hcl | Metformin Hcl | 161 | 49 |
| Trulicity | Dulaglutide | 123 | 32 |
| Jardiance | Empagliflozin | 107 | 35 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 82 | 39 |
| Mounjaro | Tirzepatide | 72 | 18 |
| Levothyroxine Sodium | Levothyroxine Sodium | 62 | 18 |
| Atorvastatin Calcium | Atorvastatin Calcium | 61 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 57 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 55 | 13 |
| Farxiga | Dapagliflozin Propanediol | 54 | 17 |
| Glipizide | Glipizide | 53 | 19 |
| Tramadol Hcl | Tramadol Hcl | 52 | 18 |
| Tresiba Flextouch U-100 | Insulin Degludec | 51 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 46 | 15 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Methimazole | Methimazole | 45 | 15 |
| Gabapentin | Gabapentin | 42 | 13 |
| Lisinopril | Lisinopril | 41 | 14 |
| Glimepiride | Glimepiride | 35 | 13 |
| Novolog Flexpen | Insulin Aspart | 34 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 32 | 11 |
| Losartan Potassium | Losartan Potassium | 31 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 14 |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,068.52 · 31 records | Globus Medical, Inc. | BOTOX, GVOKE HYPOPEN, INCEPTIV, JARDIANCE, MILD DEVICE KIT, OCTRODE, PROCLAIM, QULIPTA, QUTENZA, RELISTOR, SYNCHROMEDII, Senza, UBRELVY, VYEPTI, Vyrsa V1, XTAMPZA, ZTLido | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error